Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

CEO

Hermann Luebbert

Employees

Country

Germany

ISIN

DE0006046113

WKN

000604611

Listings

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock price today?▼

The current price of BFFTF is $2.67 USD — it has decreased by -88.25% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.

What is Biofrontera stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Biofrontera stocks are traded under the ticker BFFTF.

What is Biofrontera revenue for the last year?▼

Biofrontera revenue for the last year amounts to 34.07M USD.

What is Biofrontera net income for the last year?▼

BFFTF net income for the last year is -20.13M USD.

How many employees does Biofrontera have?▼

As of September 04, 2026, the company has 97 employees.

In which sector is Biofrontera located?▼

Biofrontera operates in the Technology sector.

When did Biofrontera complete a stock split?▼

Biofrontera has not had any recent stock splits.

Where is Biofrontera headquartered?▼

Biofrontera is headquartered in Leverkusen, Germany.